About Halozyme Therapeutics
Halozyme Therapeutics (NASDAQ:HALO) is a biotechnology firm focused on developing innovative oncology therapies and drug-delivery solutions. Specializing in its proprietary enzyme technology, the company aims to improve the absorption, distribution, metabolism, and excretion (ADME) properties of other drugs. Halozyme's key projects revolve around the ENHANZE® drug delivery technology, which allows for subcutaneous administration of biologic drugs that would otherwise require intravenous delivery. This technology not only enhances patient convenience and compliance but also has the potential to significantly reduce healthcare costs. The company's objectives are centered on expanding the use of its ENHANZE® technology through partnerships with leading pharmaceutical companies, developing its own pipeline of novel cancer treatments, and achieving global recognition for its contributions to improving therapeutic outcomes.
Snapshot
Operations
Products and/or services of Halozyme Therapeutics
- ENHANZE technology utilizes recombinant human hyaluronidase PH20 to facilitate subcutaneous drug delivery, improving efficacy and patient experience.
- PEGPH20, a pegylated version of hyaluronidase, targets tumor microenvironments for enhanced cancer therapies.
- HALO-301, a pivotal Phase 3 clinical trial investigating PEGPH20 in combination with nab-paclitaxel and gemcitabine for patients with pancreatic cancer.
- Partnerships with major pharmaceutical companies to apply ENHANZE technology across various drug candidates, enhancing delivery and expanding therapeutic potentials.
- Development of proprietary oncology therapies focusing on novel targets and pathways for effective cancer treatment.
- Continuous exploration of new therapeutic areas and technologies to expand its portfolio and address unmet medical needs.
Halozyme Therapeutics executive team
- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.President, CEO & Director
- Ms. Nicole LaBrosse CPASenior VP & CFO
- Mr. Mark Snyder Esq.Senior VP, General Counsel, Chief Compliance Officer & nd Secretary
- Ms. Cortney Caudill M.B.A.Senior VP & COO
- Ms. Tram BuiHead of Investor Relations & Corporate Communications
- Dr. Christopher Wahl M.B.A., M.D.Chief Scientific Officer
- Dr. Charles P. Theuer M.D., Ph.D.Chief Medical Officer
- Mr. Paul SpenceChief Commercial Officer
- Mr. Rhys de CallierChief Strategy Officer
- Mr. Chase Coffman Ph.D.President of Hypercon